30 results on '"Pintér, D."'
Search Results
2. Trimetazidine treatment in Parkinson's Disease: Is it a real problem or just a flame?
- Author
-
Pintér, D., primary, Kovács, M., additional, Juhász, A., additional, Harmat, M., additional, Janszky, J., additional, and Kovács, N., additional
- Published
- 2020
- Full Text
- View/download PDF
3. Long‐term successful treatment of chronic inflammatory demyelinating polyneuropathy‐like polyneuropathy induced by levodopa‐carbidopa intestinal gel with intravenous immunoglobulin
- Author
-
Pintér, D., primary, Deli, G., additional, Juhász, A., additional, Pál, E., additional, Janszky, J., additional, and Kovács, N., additional
- Published
- 2019
- Full Text
- View/download PDF
4. Repetitive transcranial magnetic stimulation can improve anxiety in Parkinson’s disease:a randomized, double-blind and controlled trial
- Author
-
Kovács, N., primary, Pál, E., additional, Weisz, A Makkos, additional, Kovács, M., additional, and Pintér, D., additional
- Published
- 2019
- Full Text
- View/download PDF
5. Repetitive transcranial magnetic stimulation can improve anxiety in Parkinson's disease: A randomized, double-blind and controlled trial
- Author
-
Juhasz, A., Makkos, A., Kovacs, M., Harmat, M., Pinter, D., and Kovacs, N.
- Published
- 2019
- Full Text
- View/download PDF
6. 04:12 PM Abstract No. 61 Medical malpractice related to inferior vena cava filter placement: how commonly are interventional radiologists named in cases?
- Author
-
Badar, Z., Tonzi, E., Choudhry, A., Pinter, D., Goel, A., and Amankwah, K.
- Published
- 2019
- Full Text
- View/download PDF
7. A uniqueLAMB3splice-site mutation with founder effect from the Balkans causes lethal epidermolysis bullosa in several European countries
- Author
-
Mayer, B., primary, Silló, P., additional, Mazán, M., additional, Pintér, D., additional, Medvecz, M., additional, Has, C., additional, Castiglia, D., additional, Petit, F., additional, Charlesworth, A., additional, Hatvani, Zs., additional, Pamjav, H., additional, and Kárpáti, S., additional
- Published
- 2016
- Full Text
- View/download PDF
8. A unique LAMB3 splice-site mutation with founder effect from the Balkans causes lethal epidermolysis bullosa in several European countries.
- Author
-
Mayer, B., Silló, P., Mazán, M., Pintér, D., Medvecz, M., Has, C., Castiglia, D., Petit, F., Charlesworth, A., Hatvani, Zs., Pamjav, H., and Kárpáti, S.
- Subjects
LAMININS ,EPIDERMOLYSIS bullosa ,INFANT diseases ,ANTISENSE DNA ,DNA mutational analysis ,POPULATION - Abstract
Background We have encountered repeated cases of recessive lethal generalized severe (Herlitz-type) junctional epidermolysis bullosa ( JEB gen sev) in infants born to Hungarian Roma parents residing in a small region of Hungary. Objectives To identify the disease-causing mutation and to investigate the genetic background of its unique carrier group. Methods The LAMB3 gene was analysed in peripheral-blood genomic DNA samples, and the pathological consequences of the lethal defect were confirmed by cutaneous LAMB3 cDNA sequencing. A median joining haplotype network within the Y chromosome H1a-M82 haplogroup of individuals from the community was constructed, and LAMB3 single-nucleotide polymorphism ( SNP) patterns were also determined. Results An unconventional intronic splice-site mutation ( LAMB3, c.1133-22G>A) was identified. Thirty of 64 voluntarily screened Roma from the closed community carried the mutation, but none of the 306 Roma from other regions of the country did. The age of the mutation was estimated to be 548 ± 222 years. Within the last year, more patients with JEB gen sev carrying the same unusual mutation have been identified in three unrelated families, all immigrants from the Balkans. Two were compound heterozygous newborns, in Germany and Italy, and one homozygous newborn died in France. Only the French family recognized their Roma background. LAMB3 SNP haplotyping confirmed the link between the apparently unrelated Hungarian, German and Italian male cases, but could not verify the same background in the female newborn from France. Conclusions The estimated age of the mutation corresponds to the time period when Roma were wandering in the Balkans. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
9. P-277: An exploratory study on the effects of mobility training in chronic stroke patients using repeated fMRI
- Author
-
de Campo, A., Landsmann, B., Pinter, D., Pichler, G., Pirker, E., Schippinger, W.M., Gattringer, T., Fazekas, F., and Enzinger, C.
- Published
- 2015
- Full Text
- View/download PDF
10. Comment on "Summing MDS-UPDRS Parts 1 + 2 (Nonmotor and Motor Experience of Daily Living): The Patient's Voice".
- Author
-
Kovács N, Aschermann Z, Harmat M, Rohonczi M, Janszky J, and Pintér D
- Subjects
- Humans, Mental Status and Dementia Tests, Parkinson Disease complications
- Published
- 2023
- Full Text
- View/download PDF
11. Antiparkinsonian Drug Reduction After Directional Versus Omnidirectional Bilateral Subthalamic Deep Brain Stimulation.
- Author
-
Pintér D, Járdaházi E, Balás I, Harmat M, Makó T, Juhász A, Janszky J, and Kovács N
- Subjects
- Humans, Antiparkinson Agents therapeutic use, Levodopa therapeutic use, Quality of Life, Treatment Outcome, Deep Brain Stimulation, Parkinson Disease complications, Subthalamic Nucleus physiology
- Abstract
Background: Several pilot trials and the Clinical Evaluation of the Infinity Deep Brain Stimulation System (PROGRESS) study have found that directional stimulation can provide a wider therapeutic window and lower therapeutic current strength than omnidirectional stimulation., Objective: We conducted a single-center, open-label, registry-based, comparative trial to test the hypothesis that directional stimulation can be associated with a greater reduction in the total daily dose of antiparkinsonian medications (ApMeds) than omnidirectional stimulation., Materials and Methods: A total of 52 patients with directional and 57 subjects with omnidirectional bilateral subthalamic deep brain stimulation (STN-DBS) were enrolled. Preoperatively and 12 months postoperatively, the dose of different ApMeds, the number of tablets used daily, the severity of motor and nonmotor symptoms using the Movement Disorder Society-sponsored Unified Parkinson Disease Rating Scale, and the health-related quality of life (HRQoL) using the 39-item Parkinson's Disease Questionnaire (PDQ-39) were assessed., Results: According to the changes in the levodopa equivalent daily dose, directional STN-DBS led to a 13% greater reduction in the total daily dose of ApMed. The 10.3% greater reduction in the dose of levodopa was the main contributor to this difference. The number of different ApMed types also could be decreased in a greater manner with directional stimulation. The improvement in the severity of motor and nonmotor symptoms was comparable; however, we detected a 15.8% greater improvement in the global HRQoL among patients with directional stimulation according to the changes in the summary index of the PDQ-39. The total electrical energy delivered per second was comparable between the groups at 12-month postoperative visit, whereas the amplitude of stimulation was significantly lower and the impedance was significantly higher with directional leads., Conclusions: Directional programming can further increase the reduction in the total daily dose of ApMed after STN-DBS. In addition, directional stimulation can have additional beneficial effects on the global HRQoL. The greater reduction of ApMed doses did not require more energy-consuming stimulation with directional stimulation., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
12. Potential clinical and economic benefits of remote deep brain stimulation programming.
- Author
-
Pintér D, Járdaházi E, Janszky J, and Kovács N
- Subjects
- Humans, Travel, Retrospective Studies, Pandemics, Travel-Related Illness, Deep Brain Stimulation methods, COVID-19 epidemiology, COVID-19 therapy
- Abstract
Deep brain stimulation (DBS) teleprogramming may help reducing travel-related and other financial burdens for patients and maintaining DBS care in special situations. To determine travel-related burdens of DBS patients and explore effects of COVID-19 on DBS care. Travel- and visit-related data of 319 patients were retrospectively analyzed for the first year, five years, and ten years after initiating DBS. Frequencies of in-person and telemedicine visits over the 18-month periods just before and after the outbreak of COVID-19 in Hungary were also compared. Average travel distance during an in-person visit was 415.2 ± 261.5 km, while average travel time was 342.1 ± 199.4 min. Travel costs for the first year, five years, and ten years were 151.8 ± 108.7, 461.4 ± 374.6, and 922.7 ± 749.1 Euros, respectively. Travel distance, age, and type and severity of disease could help identify patients who would particularly benefit from teleprogramming. We detected a significant decrease in the number of visits during COVID-19 pandemic (from 3.7 ± 2.1 to 2.4 ± 2.7; p < 0.001) which mainly resulted from the decreased frequency of in-person visits (3.6 ± 2.0 vs. 1.7 ± 1.8; p < 0.001). Our results support the introduction of DBS teleprogramming in Hungary which could save money and time for patients while maintaining a secure delivery of DBS., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
13. [Telecare in Parkinson's disease: A nationwide survey among Hungarian neurologists].
- Author
-
Pintér D, Járdaházi E, Janszky J, and Kovács N
- Subjects
- Humans, Hungary epidemiology, Neurologists, COVID-19 epidemiology, Parkinson Disease diagnosis, Parkinson Disease epidemiology, Parkinson Disease therapy, Telemedicine methods
- Abstract
Background and Purpose: COVID-19 has made providing in-person care difficult. In most countries, including Hungary, telemedicine has partly served as a resolution for this issue. Our purpose was to explore the effects of COVID-19 on neurological care, the knowledge of neurology specialists on telemedicine, and the present state of telecare in Hungary, with a special focus on Parkinson's disease (PD)., Methods: Between July and October 2021, a nationwide online survey was conducted among actively practicing Hungarian neurology specialists who were managing patients with PD., Results: A total of 104 neurologists were surveyed. All levels of care were evaluated in both publicly funded and private healthcare. Both time weekly spent on outpatient specialty consultation and the number of patients with PD seen weekly significantly decreased in public healthcare, while remained almost unchanged in private care (p<0.001); higher portion of patients were able to receive in-person care in private care (78.8% vs. 90.8%, p<0.001). In telecare, prescribing medicines has already been performed by the most (n=103, 99%). Electronic messages were the most widely known telemedicine tools (n=98, 94.2%), while phone call has already been used by most neurologists (n=95, 91.3%). Video-based consultation has been more widely used in private than public care (30.1% vs. 15.5%, p=0.001). Teleprocedures were considered most suitable for monitoring progression and symptoms of Parkinson's disease and evaluating the need for adjustments to antiparkinsonian pharmacotherapy., Conclusion: COVID-19 has had a major impact on the care of patients with PD in Hungary. Telemedicine has mitigated these detrimental effects; however, further developments could make it an even more reliable component of care.
- Published
- 2022
- Full Text
- View/download PDF
14. The effects of CRF and the urocortins on the hippocampal acetylcholine release in rats.
- Author
-
Pintér D, Balangó B, Simon B, Palotai M, Csabafi K, Dobó É, Ibos KE, and Bagosi Z
- Subjects
- Animals, Corticotropin-Releasing Hormone metabolism, Hippocampus metabolism, Peptide Fragments metabolism, Rats, Wistar, Receptors, Corticotropin-Releasing Hormone drug effects, Receptors, Corticotropin-Releasing Hormone metabolism, Urocortins metabolism, Rats, Acetylcholine metabolism, Corticotropin-Releasing Hormone pharmacology, Hippocampus drug effects, Urocortins pharmacology
- Abstract
Corticotropin-releasing factor (CRF) and the urocortins (Ucn1, Ucn2 and Ucn3) are structurally related neuropeptides which act via two distinct CRF receptors, CRF1 and CRF2, with putatively antagonistic effects in the brain. CRF and Ucn1 activate both CRF1 and CRF2, while Ucn2 and Ucn3 activate selectively CRF2. The aim of the present study was to investigate the effects of CRF, Ucn1, Ucn2 and Ucn3 on the hippocampal acetylcholine release through which they may modulate cognitive functions, including attention, learning and memory. In this purpose male Wistar rats were used, their hippocampus was isolated, dissected, incubated, superfused and stimulated electrically. The hippocampal slices were first pretreated with selective CRF1 antagonist antalarmin or selective CRF2 antagonist astressin
2 B, and then treated with non-selective CRF1 agonists, CRF or Ucn1, and selective CRF2 agonists, Ucn2 or Ucn3. The hippocampal acetylcholine release was increased significantly by CRF and Ucn1 and decreased significantly by Ucn2 and Ucn3. The increasing effect of CRF and Ucn1 was reduced significantly by antalarmin, but not astressin2 B. In contrast, the decreasing effect of Ucn2 and Ucn3 was reversed significantly by the selective CRF2, but not the selective CRF1 antagonist. Our results demonstrate that CRF and Ucn1 stimulate the hippocampal acetylcholine release through CRF1, whereas Ucn2 and Ucn3 inhibit the hippocampal acetylcholine release through CRF2. Therefore, the present study suggests the existence of two apparently opposing CRF systems in the hippocampus, through which CRF and the urocortins might modulate cholinergic activity and thereby cognitive functions., (Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
15. Trimetazidine Use in Parkinson's Disease: Is It a Resolved Problem?
- Author
-
Pintér D, Bereczki D, Ajtay A, Oberfrank F, Janszky J, and Kovács N
- Subjects
- Angina Pectoris drug therapy, Humans, Retrospective Studies, Vasodilator Agents, Parkinson Disease drug therapy, Trimetazidine therapeutic use
- Abstract
Trimetazidine (TMZ), an antianginal drug, can worsen the symptoms of movement disorders, therefore, the European Medicines Agency (EMA) recommended avoiding the use of this drug in Parkinson's disease (PD). We investigated the impact of this recommendation on the observed trend of TMZ use in PD in Hungary from 2010 to 2016 by conducting a nationwide, retrospective study of health administrative data of human subjects. Interrupted time series analyses were performed to explore changes in user trends after the EMA recommendations. We found that TMZ use in PD decreased by 6.56% in each six-month interval after the EMA intervention [a change in trend of -530.22, 95% confidence interval (CI) = -645.00 to -415.44, p < 0.001 and a decrease in level of -567.26, 95% CI = -910.99 to -223.53, p = 0.005 12 months postintervention]. TMZ discontinuation was the highest immediately after the intervention, however, its rate slowed down subsequently (a change in trend of -49.69, 95% CI = -85.14 to -14.24, p = 0.11 without significant level effects). The rate of new TMZ prescriptions did not reduce significantly, therefore, the decreased overall use was mainly attributable to the increased rate of discontinuation only. The main indications for TMZ use were circulatory system disorders, especially angina pectoris, however, off-label utilization was also considerable (40%). The EMA recommendations on TMZ use seem to be only moderately effective in Hungary. Although the number of patients with PD on the drug modestly decreased after the EMA restrictions, TMZ is still widely used in PD for both on-label and off-label indications., (Copyright © 2021 Pintér et al.)
- Published
- 2021
- Full Text
- View/download PDF
16. Minimal Clinically Important Differences for Burke-Fahn-Marsden Dystonia Rating Scale and 36-Item Short-Form Health Survey.
- Author
-
Pintér D, Janszky J, and Kovács N
- Subjects
- Aged, Globus Pallidus, Health Surveys, Humans, Minimal Clinically Important Difference, Treatment Outcome, Deep Brain Stimulation, Dystonia diagnosis, Dystonia therapy
- Abstract
Background: Although an increasing number of trials are reported on the treatment of generalized or segmental isolated dystonia, the minimal clinically important difference thresholds for the most frequently reported outcome measures are still undetermined., Objectives: To estimate the minimal clinically important difference for the Burke-Fahn-Marsden Dystonia Rating Scale and the 36-Item Short-Form Health Survey in generalized or segmental dystonia., Methods: A total of 898 paired examinations of 198 consecutive patients, aged >18 years, with idiopathic and inherited (torsin family 1 member A positive) segmental and generalized isolated dystonia were analyzed. To calculate the minimal clinically important difference thresholds, both anchor- and distribution-based methods were used simultaneously., Results: Any improvement >16.6% or worsening larger than 21.5% on the Burke-Fahn-Marsden Dystonia Rating Scale indicates a minimal, yet clinically relevant, change. Threshold values for the Burke-Fahn-Marsden Dystonia Disability Scale were 0.5 points for both decline and improvement. Cut-off scores for the Physical Component Summary, the Mental Component Summary, and the Global (Total or Overall) Score of the 36-Item Short-Form Health Survey were 5.5 and 5.5, 6.5 and 7.5, and 7.5 and 8.5 points for clinically meaningful improvement and deterioration, respectively., Conclusions: The minimal clinically important difference represents the smallest change in an outcome measure that is meaningful to patients. Our estimates for the Burke-Fahn-Marsden Dystonia Rating Scale and the 36-Item Short-Form Health Survey may allow more reliable judgment of the clinical relevance of different treatments for segmental and generalized isolated dystonia. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society., (© 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.)
- Published
- 2020
- Full Text
- View/download PDF
17. The Impact of Trimetazidine on Disease Severity and Quality of Life in Parkinson's Disease.
- Author
-
Pintér D, Juhász A, Harmat M, Janszky J, and Kovács N
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Longitudinal Studies, Male, Neuropsychological Tests, Prospective Studies, Severity of Illness Index, Surveys and Questionnaires, Parkinson Disease psychology, Quality of Life psychology, Trimetazidine adverse effects
- Abstract
Trimetazidine is contraindicated in movement disorders, however, a not negligible part of trimetazidine users is still patients with Parkinson's disease (PD). The present study aimed to objectively determine the impact of trimetazidine on the severity of symptoms and the health-related quality of life of patients with PD by measuring changes after its withdrawal. A consecutive series of 42 patients with PD using trimetazidine underwent detailed neurological and neuropsychological assessments at baseline and three months after the discontinuation of trimetazidine. Clinically relevant improvements were achieved with discontinuation of trimetazidine according to changes in scores of each part of the Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale (Part I: -25.7%, p < 0.001; Part II: -23.8%, p < 0.001; Part III: -28.5%, p < 0.001; Part IV: -30.1%, p = 0.004) and total scores of the Non-Motor Symptoms Scale (-25.6%, p = 0.004) and the Montgomery-Asberg-Depression Rating Scale (-20.1%, p = 0.001). Benefits resulting from the withdrawal of the drug also manifested in the improvement of the health-related quality of life based on changes in the summary index of the 39-item Parkinson's Disease Questionnaire (-18.2%, p = 0.031). Our results provide clinical rationale for strictly avoiding the use of trimetazidine in PD. Discontinuation of trimetazidin results in clinically relevant improvements in Parkinsonian symptoms.
- Published
- 2020
- Full Text
- View/download PDF
18. Comment on "Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiologic study".
- Author
-
Pintér D, Janszky J, and Kovács N
- Subjects
- Humans, Parkinsonian Disorders
- Published
- 2020
- Full Text
- View/download PDF
19. Which Scale Best Detects Treatment Response of Tremor in Parkinsonism?
- Author
-
Pintér D, Forjaz MJ, Martinez-Martin P, Rodriguez-Blazquez C, Ayala A, Juhász A, Harmat M, Janszky J, and Kovács N
- Subjects
- Adult, Aged, Carbidopa pharmacology, Drug Combinations, Female, Follow-Up Studies, Humans, Male, Middle Aged, Parkinsonian Disorders complications, Sensitivity and Specificity, Tremor etiology, Antiparkinson Agents pharmacology, Deep Brain Stimulation, Levodopa pharmacology, Outcome Assessment, Health Care standards, Parkinsonian Disorders drug therapy, Severity of Illness Index, Tremor drug therapy
- Abstract
Background: Several scales are available for rating the severity of tremor at present. However, the sensitivity to change of these instruments has remained to be clarified., Objective: To compare the sensitivity of the Fahn-Tolosa-Marin Tremor Rating Scale, the Part III of the Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and the MDS-UPDRS Tremor Scale to the effects of various antitremor treatments., Methods: Enrolling subjects with parkinsonism associated with tremor, we analyzed two scenarios: (1) tremor changes associated with acute levodopa challenge (n = 287) and (2) a 12-month outcome of different treatment options (n = 512) including deep brain stimulation (n = 146), levodopa/carbidopa intestinal gel infusion (n = 30), and initiating (n = 63) or adjusting oral antiparkinsonian medication (n = 273). Changes in tremor scales were assessed by effect size values (Cohen's d and eta-square)., Results: Part B of the Fahn-Tolosa-Marin Tremor Rating Scale was the most sensitive to acute levodopa challenge (Cohen's d = -1.04, η2 = 0.12). However, Part A of the Fahn-Tolosa-Marin Tremor Rating Scale showed the highest effect size, which was a small one (Cohen's d = -0.33, η2 = 0.03), for detecting a treatment-related change in the severity of tremor during long-term follow-up., Conclusions: The Fahn-Tolosa-Marin Tremor Rating Scale has a better ability to capture changes due to levodopa challenge or antiparkinsonian treatment than MDS-UPDRS Part III or MDS-UPDRS Tremor Scale.
- Published
- 2020
- Full Text
- View/download PDF
20. The Parkinson's Disease Composite Scale Is Adequately Responsive to Acute Levodopa Challenge.
- Author
-
Pintér D, Martinez-Martin P, Janszky J, and Kovács N
- Abstract
Background: The Parkinson's Disease Composite Scale (PDCS) is a recently developed easy-to-use tool enabling a timely but comprehensive assessment of Parkinson's disease (PD)-related symptoms. Although the PDCS has been extensively validated, its responsiveness to acute levodopa challenge has not been demonstrated yet., Objective: To investigate the correlation between changes in the motor examination part of the Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and the PDCS motor scores during acute levodopa challenge and calculate a cutoff range on the PDCS indicating clinically relevant improvement., Methods: A consecutive series of 100 patients with parkinsonism were assessed using the motor examination sections of the MDS-UPDRS and the PDCS at least 12 hours after the last levodopa dose and after the administration of a single dose of a suprathreshold immediate formulation of levodopa/benserazide reaching the "best ON." Result s. There was a high correlation between changes in the MDS-UPDRS and the PDCS motor scores (Spearman's rho = 0.73, p < 0.001). Receiver operating characteristic analysis revealed that a 14.6%-18.5% improvement in the PDCS motor scores corresponds to a 20-30% improvement in the MDS-UPDRS motor examination., Conclusions: The PDCS can reliably and adequately respond to an acute levodopa challenge. Any improvements in PDCS motor scores exceeding the 14.6-18.5% threshold could represent a clinically relevant response to levodopa., Competing Interests: The authors declare that they have no conflicts of interest., (Copyright © 2019 Dávid Pintér et al.)
- Published
- 2019
- Full Text
- View/download PDF
21. Minimal clinically important difference for the quality of life in essential tremor questionnaire.
- Author
-
Pintér D, Makkos A, Kovács M, Janszky J, and Kovács N
- Subjects
- Adult, Aged, Essential Tremor psychology, Female, Humans, Male, Middle Aged, Severity of Illness Index, Surveys and Questionnaires, Essential Tremor physiopathology, Minimal Clinically Important Difference, Quality of Life
- Published
- 2019
- Full Text
- View/download PDF
22. Trimetazidine and parkinsonism: A prospective study.
- Author
-
Pintér D, Kovács M, Harmat M, Juhász A, Janszky J, and Kovács N
- Subjects
- Aged, Antiparkinson Agents adverse effects, Antiparkinson Agents therapeutic use, Female, Humans, Male, Middle Aged, Prospective Studies, Parkinson Disease drug therapy, Parkinsonian Disorders drug therapy, Tremor drug therapy, Trimetazidine pharmacology
- Abstract
Background: Although trimetazidine may induce parkinsonian symptoms in some patients, no systematic characterization has been reported on parkinsonism occurring during trimetazidine treatment since the first case reports., Objective: To systematically investigate parkinsonism occurring during trimetazidine use., Methods: Thirty-three consecutive patients on trimetazidine treatment with previously unrecognized parkinsonian symptoms were enrolled. Detailed neurological and neuropsychological examinations were performed at baseline and 1 and 12 months after trimetazidine withdrawal. In cases with persisting parkinsonian symptoms and suspected de novo Parkinson's disease, antiparkinsonian treatment was initiated. Twenty of the 33 patients underwent DaTSCAN imaging., Results: After trimetazidine withdrawal, parkinsonism was completely resolved in 11 cases. The comparison of baseline data of patients with reversible and persisting parkinsonism showed that trimetazidine-induced reversible parkinsonism was mainly characterized by akinesia, rigidity, postural instability and gait disturbances (PIGD; PIGD scores: 5.3 ± 3.8 vs. 2.0 ± 1.6 points, p = 0.006) rather than tremors (tremor scores: 1.5 ± 2.2 vs. 7.7 ± 4.6 points, p = 0.000). Trimetazidine-induced reversible parkinsonism was also more symmetrical (asymmetry index: 3.1 ± 3.6 vs. 40.1 ± 22.2, p = 0.000) and milder in severity (MDS-UPDRS Part III. scores: 10.5 ± 19. vs. 30.5 ± 11.3, p = 0.040) than nonreversible parkinsonism. DaTSCAN images were normal in all trimetazidine-induced reversible parkinsonism patients, while these images were abnormal in every patient with nonreversible parkinsonism. In cases of nonreversible parkinsonism, preexisting, incipient Parkinson's disease was suspected by clinical appearance and a good response to antiparkinsonian medication., Conclusions: Mild and symmetrical appearance of parkinsonism with normal DaTSCAN results can indicate drug-induced parkinsonism. Trimetazidine discontinuation generally results in permanent remission in such cases., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
23. Changes in striatal dopamine release and locomotor activity following acute withdrawal from chronic nicotine are mediated by CRF1, but not CRF2, receptors.
- Author
-
Buzás A, Bokor P, Balangó B, Pintér D, Palotai M, Simon B, Csabafi K, Telegdy G, Szabó G, and Bagosi Z
- Subjects
- Animals, Corpus Striatum metabolism, Corticotropin-Releasing Hormone pharmacology, Dopamine metabolism, Locomotion physiology, Male, Motor Activity, Peptide Fragments pharmacology, Rats, Rats, Wistar, Substance Withdrawal Syndrome metabolism, Dopaminergic Neurons metabolism, Nicotine metabolism, Receptors, Corticotropin-Releasing Hormone metabolism
- Abstract
The aim of the present study was to investigate the participation of corticotropin-releasing factor (CRF) receptors (CRF1 and CRF2) in the alterations of the dorsal and ventral striatal dopamine release and the vertical and horizontal locomotor activity observed in rats following chronic nicotine treatment and consequent acute withdrawal. In this purpose, male Wistar rats were exposed to repeated intraperitoneal (ip) injection with nicotine or saline solution for 7 days. On the 8th day or the 9th day the rats were injected intracerebroventricularly (icv) with selective CRF1 antagonist antalarmin or selective CRF2 antagonist astressin
2B or saline solution. Thirty minutes after the icv injection the changes of the horizontal and vertical locomotor activity were recorded in an in vivo conducta system. Immediately after the behavioral recordings the changes of the dorsal and ventral striatal dopamine release were determined in an in vitro superfusion system. On the 8th day, the horizontal and vertical locomotor activities and the dorsal and ventral striatal dopamine releases increased significantly in nicotine-treated rats, compared to the saline-treated ones. On the 9th day, the horizontal locomotor activity and the dorsal striatal dopamine release increased significantly, whereas the vertical locomotor activity and the ventral striatal dopamine release decreased significantly in nicotine-treated rats, compared to the saline-treated ones. All the changes observed were attenuated significantly by antalarmin, but not astressin2B . The present study demonstrates that the changes of striatal dopamine release and locomotor activity observed following chronic nicotine treatment and consequent acute withdrawal are mediated by CRF1, but not CRF2, receptor., (Copyright © 2018 Elsevier B.V. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
24. Screening for Problematic Internet Use May Help Identify Impulse Control Disorders in Parkinson's Disease.
- Author
-
Kovács M, Makkos A, Pintér D, Juhász A, Darnai G, Karádi K, Janszky J, and Kovács N
- Subjects
- Aged, Disruptive, Impulse Control, and Conduct Disorders complications, Disruptive, Impulse Control, and Conduct Disorders diagnosis, Female, Humans, Male, Mass Screening, Middle Aged, Parkinson Disease complications, Parkinson Disease diagnosis, Risk Factors, Surveys and Questionnaires, Compulsive Behavior psychology, Disruptive, Impulse Control, and Conduct Disorders psychology, Internet, Parkinson Disease psychology
- Abstract
Background: Impulse control disorders in Parkinson's disease (PD) represent emerging problems with potentially devastating consequences. The standard screening methods for impulse control disorders are clinically imperfect. Although it is rarely reported, many patients utilize the Internet to fulfill their compulsive behaviors because of its easy accessibility. We designed a study to test the hypothesis that an active screening for excessive Internet use and Internet addiction might improve the sensitivity of identification of impulse control disorders., Methods: The standard screening method included the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease and the modified Minnesota Impulsive Disorders Interview. In the second round, the Problematic Internet Use Questionnaire was also assessed for detecting excessive Internet use., Results: While the standard approach identified 19 patients out of 106 (17.9%) with any type of impulse control disorders, screening for the problematic Internet use detected 29 patients with impulse control disorders (27.4%) having significantly better efficacy over the standard method ( p = 0.004, the McNemar test)., Conclusions: Our study suggests that the screening for problematic Internet use by the Problematic Internet Use Questionnaire is an effective, feasible, and easy-to-use add-on method for identifying PD patients with impulse control disorders more efficiently and probably at earlier stages.
- Published
- 2019
- Full Text
- View/download PDF
25. [Selection of the optimal device-aided therapy in Parkinson's disease].
- Author
-
Kovács N, Aschermann Z, Juhász A, Harmat M, Pintér D, and Janszky J
- Subjects
- Antiparkinson Agents administration & dosage, Carbidopa administration & dosage, Drug Combinations, Gels, Humans, Hungary, Levodopa administration & dosage, Quality of Life, Antiparkinson Agents therapeutic use, Carbidopa therapeutic use, Deep Brain Stimulation, Levodopa therapeutic use, Parkinson Disease drug therapy, Parkinson Disease therapy
- Abstract
For the treatment of advanced Parkinson's disease the deep brain stimulation (DBS) and the levodopa/carbidopa intestinal gel (LCIG) therapies are available in Hungary. Although they may have similar impact on the health-related quality of life and disabilities associated with the disease, they have different indications, and inclusion- and exclusion criteria. Consequently, the patient population treated with DBS and LCIG may be different. In the present review, the authors try to help the process of selection of the optimal device-aided therapy for the patients with advanced Parkinson's disease.
- Published
- 2019
- Full Text
- View/download PDF
26. Minimal clinically important difference for the historic parts of the Unified Dyskinesia Rating Scale.
- Author
-
Makkos A, Kovács M, Pintér D, Janszky J, and Kovács N
- Subjects
- Antiparkinson Agents pharmacology, Dyskinesias drug therapy, Humans, Movement Disorders drug therapy, Parkinson Disease diagnosis, Parkinson Disease drug therapy, Dyskinesias diagnosis, Minimal Clinically Important Difference, Movement Disorders diagnosis, Outcome Assessment, Health Care standards, Severity of Illness Index
- Abstract
Background: Motor complications represent an important clinical problem in the treatment of Parkinson's disease (PD). The Motor Complications Part of the Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS Part IV) and the Unified Dyskinesia Rating Scale (UDysRS) are among the most reliable instruments to evaluate these problems. The minimal clinically important difference thresholds are the smallest changes in the outcome measures that are clinically meaningful., Aims: The aim of our study was to calculate the minimal clinically important difference thresholds for the MDS-UPDRS Part IV and the historic parts of the UDysRS., Methods: A total of 1044 paired investigations of 436 patients were analyzed. Changes in the respective outcome measures (MDS-UPDRS Part IV, UDysRS Parts I and II) were compared to the Patient-rated Global Impression of Improvement scores (anchors). Subsequently, we applied receiver-operating characteristic analysis to ascertain the MCID thresholds with optimal sensitivity and specificity., Results: Any improvement greater than 2.1 points or any worsening greater than 1.8 points on UDysRS Part I represents a minimal, yet clinically meaningful change. In reference to UDysRS Part II, the smallest changes considered clinically relevant are 1.8 and 1.7 points for improvement and deterioration, respectively. The thresholds for the MDS-UPDRS Part IV are 0.9 points for improvement and 0.8 points for worsening., Conclusions: Our estimates may allow the judgment of the clinical relevance of numeric changes in the dyskinesia scales., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
27. Anxiolytic- and antidepressant-like actions of Urocortin 2 and its fragments in mice.
- Author
-
Bagosi Z, Csabafi K, Balangó B, Pintér D, Szolomájer-Csikós O, Bozsó Z, Tóth G, Telegdy G, and Szabó G
- Subjects
- Animals, Anxiety physiopathology, Depression physiopathology, Disease Models, Animal, Dose-Response Relationship, Drug, Freezing Reaction, Cataleptic drug effects, Injections, Intraventricular, Male, Maze Learning drug effects, Mice, Mice, Inbred C57BL, Peptides therapeutic use, Swimming psychology, Urocortins chemistry, Anti-Anxiety Agents therapeutic use, Antidepressive Agents therapeutic use, Anxiety drug therapy, Depression drug therapy, Urocortins therapeutic use
- Abstract
The aim of the present study was to investigate the potential anxiolytic- and antidepressant-like actions of Urocortin 2 (Ucn2) and its two fragments, Ucn2 (1-21) and Ucn2 (22-38), in mice, in an attempt to identify the biologically active sequence of this 38 amino acid neuropeptide. In this purpose, male C57BL/6 mice were treated intracerebroventricularly (icv) with 0.125, 0.25, 0.5 and 1 µg/2 µl of Ucn2, Ucn2 (1-21) or Ucn2 (22-38). After 30 min, the mice were evaluated in an elevated plus-maze test and a forced swim test for anxiety- and depression-like behavior, respectively. Each test lasted 5 min. Ucn2 at dose of 0.25 µg/2 µl and Ucn2 (1-21) at dose of 0.125 µg/2 µl, but not Ucn2 (22-38), increased significantly the number of entries into and the time spent in the open-arms, without influencing the total number of entries. In parallel, the same doses of Ucn2 and Ucn2 (1-21), but not Ucn2 (22-38), increased significantly the climbing and the swimming activity, while decreasing significantly the time of immobility. In addition, Ucn2 at doses of 0.125 µg/2 µl and 0.5 µg/2 µl decreased significantly the time of immobility, but they did not change the other parameters. The present study demonstrates that Ucn2 exerts anxiolytic- and antidepressant-like effects in C57BL/6 mice, which are mediated by the N-terminal, but not the C-terminal fragment of the peptide. The establishment of the smallest active sequence by further fragmentation of Ucn2 (1-21) may allow the synthesis of new anxiolytic and antidepressant drugs., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
28. Selective CRF2 receptor agonists ameliorate the anxiety- and depression-like state developed during chronic nicotine treatment and consequent acute withdrawal in mice.
- Author
-
Bagosi Z, Palotai M, Simon B, Bokor P, Buzás A, Balangó B, Pintér D, Jászberényi M, Csabafi K, and Szabó G
- Subjects
- Animals, Anxiety etiology, Anxiety metabolism, Corticosterone blood, Depression metabolism, Depression pathology, Disease Models, Animal, Drug Evaluation, Preclinical, Hypothalamo-Hypophyseal System drug effects, Hypothalamo-Hypophyseal System metabolism, Infusions, Intraventricular, Male, Mice, Motor Activity drug effects, Motor Activity physiology, Nicotine pharmacology, Nicotinic Agonists pharmacology, Pituitary-Adrenal System drug effects, Pituitary-Adrenal System metabolism, Receptors, Corticotropin-Releasing Hormone metabolism, Substance Withdrawal Syndrome metabolism, Substance Withdrawal Syndrome psychology, Tobacco Use Disorder metabolism, Tobacco Use Disorder psychology, Urocortins administration & dosage, Anxiety drug therapy, Depression drug therapy, Psychotropic Drugs administration & dosage, Receptors, Corticotropin-Releasing Hormone agonists, Substance Withdrawal Syndrome drug therapy, Tobacco Use Disorder drug therapy
- Abstract
The aim of the present study was to investigate the effects of the selective agonists of the corticotropin-releasing factor (CRF) 2 receptor, urocortin 2 (UCN 2) and urocortin 3 (UCN 3), on the anxiety- and depression-like signs induced by acute nicotine withdrawal in mice. In order to do so, male CFLP mice were exposed for 7 days to repeated intraperitoneal (IP) injection with nicotine or saline solution and 1day of acute withdrawal and then a single intracerebroventricular (ICV) injection with UCN 2, UCN 3 or saline solution. After 30min the mice were observed in an elevated plus-maze test or a forced swim test, for anxiety- and depression-like behavior. After 5min of testing, the plasma corticosterone concentration reflecting the activity of the hypothalamic-pituitary-adrenal (HPA) axis was also determined by a chemo-fluorescent method. Half of the animals were treated ICV and evaluated on the 8th day, the other half on the 9th day. On the 8th day, nicotine-treated mice presented signs of anxiolysis and depression, but no significant elevation of the plasma corticosterone concentration. On the 9th day, nicotine-treated mice exhibited signs of anxiety and depression and a significant increase of the plasma corticosterone levels. Central administration of UCN 2 or UCN 3 ameliorated the anxiety- and depression-like state including the hyperactivity of the HPA axis, developed during acute withdrawal following chronic nicotine treatment. The present study suggests that selective CRF2 receptor agonists could be used as a therapy in nicotine addiction., (Copyright © 2016 Elsevier B.V. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
29. The effects of CRF and urocortins on the hippocampal glutamate release.
- Author
-
Bagosi Z, Balangó B, Pintér D, Csabafi K, Jászberényi M, Szabó G, and Telegdy G
- Subjects
- Amygdala drug effects, Animals, Hippocampus drug effects, Hypothalamus metabolism, Male, Rats, Wistar, Corticotropin-Releasing Hormone pharmacology, Glutamic Acid metabolism, Hypothalamo-Hypophyseal System drug effects, Hypothalamus drug effects, Pituitary-Adrenal System drug effects, Urocortins pharmacology
- Abstract
Corticotropin-releasing factor (CRF) is a hypothalamic neurohormone and an extrahypothalamic neurotransmitter that regulates the hypothalamic-pituitary-adrenal (HPA) axis. The urocortins (UCN I, UCN II and UCN III) are CRF-related peptides, which may also regulate the HPA axis directly or indirectly, by modulation of extrahypothalamic neurotransmitters, such as amygdalar GABA and hippocampal glutamate. Our previous in vitro superfusion studies have already demonstrated that CRF and UCN I stimulate the amygdalar GABA release in rats. The aim of the present study was to investigate the effects of CRF, UCN I, UCN II and UCN III on the glutamate release elicited electrically from rat hippocampal slices in similar in vitro conditions. In order to investigate the participation of CRF receptors (CRFR1 and CRFR2) in this process, hippocampal slices were pretreated with antalarmin, a selective antagonist of CRFR1 or astressin 2B, a selective antagonist of CRFR2. CRF and UCN I at 100 nM decreased significantly the hippocampal glutamate release evoked by electrical stimulation. In contrast, 100 nM of UCN II and UCN III did not affect significantly the hippocampal glutamate release enhanced by electrical stimulation. The decreasing effects of CRF and UCN I were reversed by antalarmin, but not by astressin 2B, both being administered in equimolar doses. Our results demonstrate that CRF and UCN I inhibit the glutamate release in the hippocampus via CRFR1 and that CRFR2 does not participate to this process. Based on the previous and the present results we conclude that CRFR1 agonists can activate the HPA axis not only directly, but also indirectly by increasing the amygdalar GABA release and decreasing the hippocampal glutamate release., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
30. Antimicrobial susceptibility and genotyping analysis of Hungarian Neisseria gonorrhoeae strains in 2013.
- Author
-
Nemes-Nikodém É, Brunner A, Pintér D, Mihalik N, Lengyel G, Marschalkó M, Kárpáti S, Szabó D, and Ostorházi E
- Subjects
- Drug Resistance, Bacterial, Female, Genotype, Humans, Hungary, Male, Microbial Sensitivity Tests, Neisseria gonorrhoeae classification, Neisseria gonorrhoeae genetics, Time Factors, Neisseria gonorrhoeae drug effects
- Abstract
Emergence and spread of antimicrobial resistance in Neisseria gonorrhoeae is a major public health concern worldwide. The current study aims to determine the antimicrobial resistance in N. gonorrhoeae and associated molecular typing to enhance gonococcal antimicrobial surveillance in Hungary. In the National N. gonorrhoeae Reference Laboratory of Hungary 187 N. gonorrhoeae infections were detected in 2013, antibiograms were determined for all the isolated strains, and 52 (one index strain from every sexually contact related group) of them were also analysed by the N. gonorrhoeae multi-antigen sequence typing (NG-MAST) method. Twenty-two different NG-MAST sequence types (STs) were identified, of which 8 STs had not been previously described. In Hungary, the highly diversified gonococcal population displayed high resistance to penicillin, ciprofloxacin and tetracycline (the antimicrobials previously recommended for gonorrhoea treatment). Resistance to the currently recommended extended spectrum cephalosporines were rare: only two of the expected strains, an ST 1407 and an ST 210, had cefixime MIC above the resistance breakpoint. By the revision of our National Treatment Guideline, it must be considered, that the azithromycin resistance is about 60% among the four most frequently isolated STs in Hungary.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.